Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity of Recombinant vs Cell-Based vs Egg-Based Influenza Vaccines
NCT05479370Phase 3Completed
- Sponsor
- Tan Tock Seng Hospital
- Start
- Sep 2022
- Primary completion
- Apr 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of influenza vaccine, recombinant hemagglutinin in influenza, sponsored by Tan Tock Seng Hospital. Started Sep 2022; status: completed.
02
Drugs
influenza vaccine, recombinant hemagglutinin
03
Conditions
influenza
Beyond the preview
Go deeper on NCT05479370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05479370.